

Infections Primitives de l'Aorte



Xavier Bérard





Définition & épidémiologie

 Called "mycotic" because of their mushroom-like appearance, but recent consensus proposed Infected Native Aortic Aneurysm, INAA

• Their incidence is up to 1.3% of all aortic aneurysms in Western countries and reportedly higher in East Asia.

• Most patients are male (3:1) and tend to be younger (mean age 69-70 years) than those with a degenerative non-infected aneurysm (74-78 years).








Anatomie

• The most common locations are in the abdominal aorta (≈70%) and thoracic aorta (≈30%); visceral MAs are rare (accounting for <1%).

 85% percent of atherosclerotic aortic aneurysms are located in the infrarenal segment, whereas most aortic MAs are suprarenal



Microbiologie

- S. aureus and and coagulase-negative staphylococci (at least 50-60%)
- Nontyphoid Salmonella (30-40%)
- Others
 - Enterococcus species
 - Streptococcus pneumoniae
 - Clostridium species
 - Coxiella burnetii
 - Mycobacteria
 - Fungi (primary aorto-enteric fistula)









Les recommendations

The main recommendations about mycotic aneurysms come from the European and the American Societies of Vascular Surgery

Although they do not sensibly differ in terms of content, they are discussed in the AAA treatment guidelines for the ESVS and in those of infected graft for SVS

Eur J Vasc Endovasc Surg (2019) 57, 8-93

Editor's Choice — European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms

AHA SCIENTIFIC STATEMENT

Vascular Graft Infections, Mycotic Aneurysms, and Endovascular Infections

A Scientific Statement From the American Heart Association

Diagnostic

Table 9.1. Suggested diagnostic criteria of mycotic aortic aneurysm. ⁶⁸⁸		
Combination of the	e following factors:	
Clinical	Abdominal/back pain	
presentation	Fever	
	Sepsis/shock	
Laboratory	C-reactive protein ↑	
and culture	Leucocytes ↑	
	Positive blood culture or aortic	
	tissue culture	
Radiologic	Saccular/multi-lobular/eccentric	
findings on CT	Peri-aortic gas/soft tissue mass	
	Rapid expansion (days) and/or rupture	
	Atypical location (e.g. para-visceral)	
	or multiple aneurysms in different	
	locations	


Recommendation 106		
It is recommended that the diagnosis of a mycotic aortic aneurysm is based on a combination of clinical, laboratory, and imaging parameters		
Class	Level	References
I	C	[692,689,690]

General Principles

 Patients should be managed by a team of experts in vascular diseases and surgery, cardiology and cardiovascular surgery, critical care medicine (intensivists), radiology, infectious diseases, and microbiology in a facility with emergency access to these services (Class I; Level of Evidence C).








Traitement Chirurgical


Recommendation 108		
Mycotic aneurysm repair is recommended irrespective of aneurysm size		
Class	Level	References
I	C	[710,690]


Surgical techniques used in mycotic aneurysm repair should be considered based on patient status, local routines, and team experience, with endovascular repair being an acceptable alternative to open repair Class Level References [702,698,694,690]















In the emergency setting of active bleeding complicating abdominal aortic graft/endograft infection with or without aorto-enteric fistula, initial treatment with an endograft should be considered, but only as a temporary measure.

Class	Level	References
IIa	С	[197, 198]



Les endoprothèses, une solution de sauvetage (bridge surgery)



Bridge for Primary abdominal aorto-enteric Fistula
Gore C3 for bleeding





La chirurgie endovasculaire

3. Endovascular therapy

- a. EVT may be considered as a <u>bridge therapy</u> to later open surgical management in these patients (Class IIb; Level of Evidence C):
 - i. those with rupture with unstable hemodynamics,
 - ii. those with uncontrolled bleeding with aortoenteric fistula or aortobronchial fistula, or
 - iii. those who are unfit for open surgical repair because of underlying comorbid conditions.
- b. After initial placement of the endovascular device, removal of the device, resection of the aortic MA, and aortic reconstruction may be considered (Class IIb; Level of Evidence C).

1. Endovascular device therapy may be considered in patients who are unstable hemodynamically or who are unable to tolerate an open surgical procedure as a bridge procedure to later open surgical repair (Class Ilb; Level of Evidence C).






For patients with an abdominal aortic vascular graft/endograft infection, in situ reconstruction with autologous vein should be considered as the preferred method.

Class	Level	References
IIa	С	[17, 66, 69, 142, 143, 145, 148, 180, 200]
















For patients with abdominal aortic vascular graft/endograft infection, cryopreserved allografts, silver coated grafts, rifampicin bonded polyester grafts or bovine pericardium should be considered as alternative solutions.

Class	Level	References
IIa	С	[17, 66, 69, 142, 143, 145, 148, 180, 200]







Infected FEVAR removed and replaced by Silver+Triclosan Graft





Infected Aorto bifemoral graft removed and replaced by arterial allograft

Lifelong imaging follow up is recommended after in situ reconstruction with cryopreserved allografts for abdominal aortic vascular graft/endograft infection, in order to detect allograft degeneration.

Class	Level	References
I	C	[147, 148, 150, 153]




Ruptured defrost allograft artery






In surgical repair of aortic abdominal graft/endograft infection with aorto-enteric fistula, omentoplasty or transfer of autologous vascularised tissue to cover the vascular reconstruction is recommended.

Class	Level	References
I	В	[200]








Omentoplasty





Accepted of publication September 2021

Fifteen-year, single-center experience with in situ reconstruction for infected native aortic aneurysms

Xavier Berard, MD, PhD,* Anne-Sophie Battut, MD,* Mathilde Puges, MD,b Mathilde Carrer, MD,b Katherine Stenson, MD,d Charles Cazanave, MD, PhD,b Laurent Stecken, MD,c Caroline Caradu, MD, PhD,* and Eric Ducasse, MD, PhD,* Bordeaux, France; and London, UK

ABSTRACT

Objective The purpose of the present study was to evaluate the survival and freedom from reinfection for patients with infected native aortic aneurysms (INAAs) treated with in situ revascularization (ISR), using either open surgical repair (OSR) or endovascular aneurysm repair (EVAR), and to identify the predictors of outcome.

Methods: Patients with INAAs who had undergone ISR from January 2005 to December 2020 were included in the present retrospective single-center study. The diagnosis of INAAs required a combination of two or more of the following criteria: (1) clinical presentation, (2) laboratory results, (3) imaging findings, and (4) intraoperative findings. The primary endpoint was 30-day mortality. The secondary endpoints were in-hospital mortality, estimated survival, patency, and freedom from reinfection using the Kaplan-Meier method. The predictive factors for adverse outcomes were evaluated using the Mann-Whitney U test or the Fisher exact test and multivariate regression analysis.

Results: A total of 65 patients (53 men [81596]; median age, 69.0 years, interquartile range, 615-75.0 years) were included, 31 (47796) were immunocompromised, 60 were symptomatic (92.3%), and 32 (49.2%) had presented with rupture, including 3 aortocaval fistulas (4.6%) and 12 aortocenteric fistulas (18.5%). The most common location was infrarenal (n=39,60.0%). Of the 65 patients, 55 (84.6%) had undergone primary OSR with ISR, 3 (4.6%) had required EVAR as a bridge to OSR, and 8 (12.3%) had undergone EVAR as definitive treatment. The approach was a midline laparotomy for 44 patients (67.7%), mostly followed by reconstruction and aortic—aortic bypass (n=28,40.6%) and the use of a silver and triclosan Dacron graft (n=30,43.5%). Causative organisms were identified in 55 patients (84.6%). The 30-day and in-hospital mortality rates were 6.2% (n=4) and 10.8% (n=7). The median follow-up was 33.5 months (interquartile range, 13.6-62.3 months). The estimated 1- and 5-year survival rates were 79.7% (95% confidence interval [CI], 67.6%-87.7%) and 67.4% (95% CI, 51.2%-79.3%). The corresponding freedom from reinfection rates were 92.5% (95% CI, 81.1%-97.1%) and 79.4% (95% CI, 59.1%-90.3%). On multivariate analysis, in-hospital mortality increased with uncontrolled sepsis (P<0.000), rapidly expanding aneurysms (P=0.008), and fusiform aneurysms (P=0.008). The incidence of reinfection increased with longer operating times (P=0.008).


Conclusions: The selective use of ISR and OSR combined with targeted antimicrobial therapy functioned reasonably well in the treatment of INAAs, although larger, prospective, multicenter studies with appropriately powered comparative cohorts are necessary to confirm our findings and to determine the best vascular substitute and precise role of EVAR as a bridge to OSR or definitive treatment. (I) Vasc Surg 2021; =1-12.)

Keywords: Aneurysm; Aortic rupture; Aortitis; Aortoenteric fistula; Infected native aortic aneurysm; Mycotic aneurysm

- Our Bordeaux Cohort
- From 2005 to 2020
- 65 patients with mycotic aortic aneuryms







Résultats

65 patients

- 53 men (81.5%)
- median age 69.0 years
- 31 (47.7%) immunocompromised.


Clinical presentation


- 60 symptomatic (92.3%)
- 32 (49.2%) ruptures
 - 3 aortocaval **fistulae** (4.6%)
 - 12 aorto-enteric **fistulae** (18.5%).


The most common location was infrarenal.





































Traitement Chirurgical

- 55 (84.6%) **primary OSR with ISR**
- 3 (4.6%) **EVAR** as a **bridge** to OSR
- 8 (12.3%) **EVAR** as **definitive** treatment.



The most common approach:

- a midline laparotomy (n=44; 67.7%)
- reconstruction and aorto-aortic bypass (n=28; 40.6%)
- use of a silver & triclosan Dacron graft (n=30; 43.5%).






1-year survival: 79.7% (95%CI: 67.6-87.7)

Survie

5-year survival: 67.4% (95%CI: 51.2-79.3);







Mortalité

30-day mortality : 6.2% (n=4)

In-hospital mortality: 10.8% (n=7)

90-day mortality: 18.5% (n=12)

In-hospital mortality increased with:

- uncontrolled sepsis (p<.0001)
- rapidly expanding aneurysms (p=.008)
- fusiform aneurysms (p=.03).



Variables

In-hospital mortality

Cancer

Immunosuppressed status

Hemoglobin <10g/dL

White Blood cell count (/mm3)

- ➡ Uncontrolled sepsis
- Rapidly expanding aneurysms (>5mm/6mo)
- Pseudo-aneurysm (vs Fusiform) Resistant microorganisms Fungal co-infection

Overall Mortality

Pseudo-aneurysm (vs Fusiform)

Rupture

Fever

Uncontrolled sepsis

Rapidly expanding aneurysms

(>5mm/6mo)

Fungal co-infection

Antibiotics initiated before surgery

After MDT

GI tract repair

EVAR as definitive treatment


Secondary abscess drainage

Repeat aortic surgery



Survie sans réinfection

Entire cohort







Reinfection

Seven aortic graft reinfections were noted and only one ongoing infection after EVAR as definitive treatment; they all occurred after the cessation of antimicrobial therapy.

Reinfection rates are higher when a **gastrointestinal tract repair** is needed during index procedure (p=.03), and they grow as **operating time** rises (p<.0001).

No significant association was found with the type of vascular substitute or vascular repair, nor the different microorganisms or antimicrobial regimens.






Microbiologie

Causative organisms were identified in **55 patients** (84.6%).

19 patients (29.2%) received antimicrobial therapy before surgery









Cas particulier des fistules digestives

- Not so rare 12 out 65 mycotic AAA patients (18,5%) in our Bordeaux Cohort
- Most frequent location duodenum











Les prélèvements peropératoires

- Biopsie de paroi aortique pathologique avec envoi en (10 pots)
- Bactériologie x 5 pots (dont un pot à congeler pour d'éventuelles PCR)
- Mycobactériologie x 1 pot
- Mycologie x 2 pots
- Anatomopathologie (1 pot formol) et immunohistochimie (1 pot sérum physiologique)

Traitement anti-infectieux probabiliste

• à débuter en l'absence de documentation microbiologique en pré-opératoire si sepsis ou choc septique, sinon en per-opératoire après les prélèvements

- Aortites communautaires (situation quasi-exclusive)
- Céfotaxime 2 g sur 30 min 3 fois par jour + gentamicine 8 mg/kg sur 30 min 1 x /j
- Si fistule aorto-digestive : + métronidazole 500 mg 3 x /j + caspofungine 70 mg sur 1 h 1 x /j
- Allergie aux bêta-lactamines
- Aztréonam 2 g sur 30 min 3 x /j + daptomycine 10 mg/kg sur 30 min 1 x /j + gentamicine 8 mg/kg sur 30 min 1 x /j

4 Messages importants

- 1. Pathologie rare mais risque de rupture majeur
- 2. Evolution (très) rapide
- 3. Prise en charge en équipe pluri disciplinaire
- 4. Suivi post-opératoire rigoureux pour détecter les signes de reinfections (ou d'infection persistante endoprothèse+++)